Drugs / Lanston
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03065868 | Dec 2015 → Apr 2019 | Helicobacter pylori infectious disease, stomach polyp | Kyungpook National University Hospital | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06439563 Comparator | Oct 2024 → Aug 2027 expected | peptic ulcer disease | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT01308177 Background | Mar 2011 → Mar 2012 | bleeding disorder, vascular-type, ulcer disease | Samsung Medical Center | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lanston | “comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days” NCT01308177 ↗ |